Introduction: The overactive bladder syndrome (OAB) is one of the most common and bothersome subsets of lower urinary tract symptoms (LUTS), affecting predominantly the aged population, with a worldwide distribution. This syndrome has not been completely understood, yet the aging process and the decreased blood flow to the bladder have been highlighted as closely related to this phenomenon. Materials and Methods: We performed a search on the online database PubMed/MEDLINE with the following MESH terms: ‘Overactive Bladder AND (Ischemia OR Aging OR Vascular Disease)'. We considered manuscripts written in English and published in the last 10 years (2004-2014, October). Additional manuscripts, such as referenced by reviews, were further included. Results: The aging process and the structural and functional changes resulting from an ischemic process emerge as important features that contribute to OAB. The ischemic-induced molecular and structural modifications that occur in the bladder have only recently been the objective of thorough studies, which link cardiovascular risk factors, vascular lesions and OAB. New animal models are being created to test new areas of treatment or prevention of ischemic-induced bladder dysfunction. Conclusion: Recent data point out that several physiological and pathological modifications that occur in the bladder associated with OAB and aging are closely related to ischemia.

Keywords:
Overactive bladder, Ischemia, Lower urinary tract symptoms, Aging, Vascular disease
1.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
2.
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1314.
3.
Ikeda Y, Nakagawa H, Ohmori-Matsuda K, Hozawa A, Masamune Y, Nishino Y, et al: Risk factors for overactive bladder in the elderly population: a community-based study with face-to-face interview. Int J Urol 2011;18:212-218.
4.
Wehrberger C, Madersbacher S, Jungwirth S, Fischer P, Tragl KH: Lower urinary tract symptoms and urinary incontinence in a geriatric cohort - a population-based analysis. BJU Int 2012;110:1516-1521.
5.
Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, et al: The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006;50:1050-1057.
6.
Sung W, You H, Yoon TY, Lee SJ: Socioeconomic costs of overactive bladder and stress urinary incontinence in Korea. Int Neurourol J 2012;16:23-29.
7.
McGrother CW, Donaldson MM, Hayward T, Matthews R, Dallosso HM, Hyde C, et al: Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing 2006;35:16-24.
8.
Griebling TL: Overactive bladder in elderly men: epidemiology, evaluation, clinical effects, and management. Curr Urol Rep 2013;14:418-425.
9.
Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I: The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388-1395.
10.
Smith AL, Nissim HA, Le TX, Khan A, Maliski SL, Litwin MS, et al: Misconceptions and miscommunication among aging women with overactive bladder symptoms. Urology 2011;77:55-59.
11.
Amundsen CL, Parsons M, Tissot B, Cardozo L, Diokno A, Coats AC: Bladder diary measurements in asymptomatic females: functional bladder capacity, frequency, and 24-hr volume. Neurourol Urodyn 2007;26:341-349.
12.
Elbadawi A, Yalla SV, Resnick NM: Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol 1993;150(5 pt 2):1668-1680.
13.
Blatt AH, Brammah S, Tse V, Chan L: Transurethral prostate resection in patients with hypocontractile detrusor - what is the predictive value of ultrastructural detrusor changes? J Urol 2012;188:2294-2299.
14.
Elbadawi A, Yalla SV, Resnick NM: Structural basis of geriatric voiding dysfunction. IV. Bladder outlet obstruction. J Urol 1993;150(5 pt 2):1681-1695.
15.
Elbadawi A, Yalla SV, Resnick NM: Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol 1993;150(5 pt 2):1657-1667.
16.
Lai HH, Boone TB, Thompson TC, Smith CP, Somogyi GT: Using caveolin-1 knockout mouse to study impaired detrusor contractility and disrupted muscarinic activity in the aging bladder. Urology 2007;69:407-411.
17.
Daly DM, Nocchi L, Liaskos M, McKay NG, Chapple C, Grundy D: Age-related changes in afferent pathways and urothelial function in the male mouse bladder. J Physiol 2014;592(pt 3):537-549.
18.
Jin LH, Lee HJ, Shin HY, Choi BH, Yoon SM, Park CS, et al: Development and changes with age of detrusor overactivity in spontaneous hypertensive rats as observed by simultaneous registrations of intravesical and intraabdominal pressures. Int Neurourol J 2011;15:192-198.
19.
Kregel K, Zhang HJ: An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 2007;292:R18-R36.
20.
Chung HY, Sung B, Jung KJ, Zou Y, Yu BP: The molecular inflammatory process in aging. Antioxid Redox Signal 2006;8:572-581.
21.
Nocchi L, Daly DM, Chapple C, Grundy D: Induction of oxidative stress causes functional alterations in mouse urothelium via a TRPM8-mediated mechanism: implications for aging. Aging Cell 2014;13:540-550.
22.
Masuda H, Kihara K, Saito K, Matsuoka Y, Yoshida S, Chancellor MB, et al: Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int 2008;101:775-780.
23.
Homan T, Tsuzuki T, Dogishi K, Shirakawa H, Oyama T, Nakagawa T, et al: Novel mouse model of chronic inflammatory and overactive bladder by a single intravesical injection of hydrogen peroxide. J Pharmacol Sci 2013;121:327-337.
24.
Tarcan T, Siroky MB, Krane RJ, Azadzoi KM: Isoprostane 8-epi PGF2alpha, a product of oxidative stress, is synthesized in the bladder and causes detrusor smooth muscle contraction. Neurourol Urodyn 2000;19:43-51.
25.
Tyagi P, Tyagi V, Qu X, Lin HT, Kuo HC, Chuang YC, et al: Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population. Int Urol Nephrol 2014;46:871-877.
26.
Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, Vodovotz Y, et al: Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 2010;42:629-635.
27.
Ghoniem G, Faruqui N, Elmissiry M, Mahdy A, Abdelwahab H, Oommen M, et al: Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J 2011;22:953-961.
28.
Liu HT, Chen CY, Kuo HC: Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int 2011;107:799-803.
29.
Antunes-Lopes T, Pinto R, Barros SC, Botelho F, Silva CM, Cruz CD, et al: Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol 2013;189:359-365.
30.
Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S: The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol 2006;50:581-586.
31.
Uzun H, Çiçek Y, Kocaman SA, Durakoğlugil ME, Zorba OÜ: Increased pulse-wave velocity and carotid intima-media thickness in patients with lower urinary tract symptoms. Scand J Urol 2013;47:393-398.
32.
Pinggera GM, Mitterberger M, Steiner E, Pallwein L, Frauscher F, Aigner F, et al: Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int 2008;102:470-474.
33.
Wada N, Watanabe M, Kita M, Matsumoto S, Kakizaki H: Analysis of bladder vascular resistance before and after prostatic surgery in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Neurourol Urodyn 2012;31:659-663.
34.
Bunn F, Kirby M, Pinkney E, Cardozo L, Chapple C, Chester K, et al: Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract 2015;69:199-217.
35.
Ohgaki K, Horiuchi K, Kondo Y: Association between metabolic syndrome and male overactive bladder in a Japanese population based on three different sets of criteria for metabolic syndrome and the overactive bladder symptom score. Urology 2012;79:1372-1378.
36.
Bschleipfer T, Dannenmaier AK, Illig C, Kreisel M, Gattenlöhner S, Langheinrich AC, et al: Systemic atherosclerosis causes detrusor overactivity: functional and morphological changes in hyperlipoproteinemic apoE-/-LDLR-/- mice. J Urol 2015;193:345-351.
37.
Yoshida M, Masunaga K, Nagata T, Satoji Y, Shiomi M: The effects of chronic hyperlipidemia on bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits. Neurourol Urodyn 2010;29:1350-1354.
38.
Juan YS, Li S, Levin RM, Kogan BA, Schuler C, Leggett RE, et al: The effect of ischemia/reperfusion on rabbit bladder - role of Rho-kinase and smooth muscle regulatory proteins. Urology 2009;73:1126-1130.
39.
Nomiya M, Yamaguchi O, Andersson KE, Sagawa K, Aikawa K, Shishido K, et al: The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat. Neurourol Urodyn 2012;31:195-200.
40.
Nomiya M, Yamaguchi O, Akaihata H, Hata J, Sawada N, Kojima Y, et al: Progressive vascular damage may lead to bladder underactivity in rats. J Urol 2014;191:1462-1469.
41.
Shenfeld OZ, Meir KS, Yutkin V, Gofrit ON, Landau EH, Pode D: Do atherosclerosis and chronic bladder ischemia really play a role in detrusor dysfunction of old age? Urology 2005;65:181-184.
42.
Zhang Q, Siroky M, Yang JH, Zhao Z, Azadzoi K: Effects of ischemia and oxidative stress on bladder purinoceptors expression. Urology 2014;84:1249.e1-e7.
43.
Azadzoi KM, Yalla SV, Siroky MB: Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol 2007;178:710-715.
44.
Azadzoi KM, Radisavljevic ZM, Golabek T, Yalla SV, Siroky MB: Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder. J Urol 2010;183:362-369.
45.
Azadzoi KM, Chen BG, Radisavljevic ZM, Siroky MB: Molecular reactions and ultrastructural damage in the chronically ischemic bladder. J Urol 2011;186:2115-2122.
46.
Azadzoi KM, Shinde VM, Tarcan T, Kozlowski R, Siroky MB: Increased leukotriene and prostaglandin release, and overactivity in the chronically ischemic bladder. J Urol 2003;169:1885-1891.
47.
Azadzoi KM, Heim VK, Tarcan T, Siroky MB: Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanoids. Neurourol Urodyn 2004;23:258-264.
48.
Lee JG, Levin RM, Krasnopolsky L, Wein AJ, Longhurst PA: Effects of the peptide leukotriene receptor antagonist ICI 198, 615 on the in vivo and in vitro changes in guinea pig bladder function which occur after sensitization with ovalbumin. J Urol 1995;154:1217-1221.
49.
Kim JC, Park EY, Seo SI, Park YH, Hwang TK: Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006;175:1773-1776; discussion 1776.
50.
Demirbas A, Sarici H, Kilinc MF, Telli O, Ozgur BC, Doluoglu OG, et al: The relationship between acidic urinary pH and overactive bladder: alkalization of urine improves the symptoms of overactive bladder. Urol Int 2015, Epub ahead of print.
51.
Das AK, Leggett RE, Whitbeck C, Eagen G, Levin RM: Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol Urodyn 2002;160-166.
52.
Inoue S, Saito M, Tsounapi P, Dimitriadis F, Ohmasa F, Kinoshita Y, et al: Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat. BJU Int 2012;110(2 pt 2):E118-E124.
53.
Pinggera GM, Mitterberger M, Pallwein L, Schuster A, Herwig R, Frauscher F, et al: Alpha-blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 2008;101:319-324.
54.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398.
55.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al: The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-131.
56.
Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M, Keys T, et al: Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol 2013;189:754-761.
57.
Sawada N, Nomiya M, Hood B, Koslov D, Zarifpour M, Andersson KE: Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol 2013;64:664-671.
58.
Limberg BJ, Andersson KE, Aura Kullmann F, Burmer G, de Groat WC, Rosenbaum JS: β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res 2010;342:295-306.
59.
Wagg A, Cardozo L, Nitti VW, Castro-Diaz D, Auerbach S, Blauwet MB, et al: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing 2014;43:666-675.
60.
Yun JH, Kim JH, Kim JH, Lee SW, Yang HJ, Doo SW, et al: Can we decide the optimal initial treatment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective, open-label study. Urol Int 2014;93:338-343.
61.
Matsui T, Oka M, Fukui T, Tanaka M, Oyama T, Sagawa K, et al: Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia. Int J Urol 2012;19:669-675.
62.
Kim JW, Jang HA, Bae JH, Lee JG: Effects of coenzyme Q10 on bladder dysfunction induced by chronic bladder ischemia in a rat model. J Urol 2013;189:2371-2376.
63.
Radu F, Leggett RE, Schuler C, Levin RM: The effect of antioxidants on the response of the rabbit urinary bladder to in vitro ischemia/reperfusion. Mol Cell Biochem 2011;355:65-73.
64.
Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M, Yamaguchi O, et al: Effect of melatonin on chronic bladder-ischaemia-associated changes in rat bladder function. BJU Int 2013;112:E221-E230.
65.
Chen S, Zhang HY, Zhang N, Li WH, Shan H, Liu K, et al: Treatment for chronic ischaemia-induced bladder detrusor dysfunction using bone marrow mesenchymal stem cells: an experimental study. Int J Mol Med 2012;29:416-422.
66.
Huang YC, Shindel AW, Ning H, Lin G, Harraz AM, Wang G, et al: Adipose derived stem cells ameliorate hyperlipidemia associated detrusor overactivity in a rat model. J Urol 2010;183:1232-1240.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.